NTHI: Neonc Technologies Holdings, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
21 institutions reported holding $14.30M of Neonc Technologies Holdings, Inc. on Form 13F (27 the quarter before). 1 opened a new position and 8 sold out. Shares held by institutions: +9%.
| Largest holders | Shares | Value |
|---|---|---|
| Cinctive Capital Management LP | 1,607,464 | $7.28M |
| VANGUARD CAPITAL MANAGEMENT LLC | 504,171 | $2.28M |
| BANK OF AMERICA CORP /DE/ | 224,412 | $1.02M |
| Westmount Partners, LLC | 197,178 | $893K |
| BlackRock, Inc. | 179,850 | $815K |
| GEODE CAPITAL MANAGEMENT, LLC | 166,120 | $753K |
| VANGUARD FIDUCIARY TRUST CO | 91,480 | $414K |
| STATE STREET CORP | 43,170 | $196K |
| NORTHERN TRUST CORP | 35,871 | $162K |
| Global Retirement Partners, LLC | 27,790 | $126K |
Clinical trial readouts
3 Phase 2 or 3 trials by Neonc Technologies Holdings, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-11-30 (est.) | Perillyl alcohol | Glioblastoma Multiforme | Phase 1/2 | 49 | Enrollment complete | NCT02704858 |
| 2026-12-30 (est.) | NEO100 | Residual, Progressive or Recurrent Grade II or III Meningiom | Phase 2 | 30 | Recruiting | NCT05023018 |
| 2027-02-28 (est.) | NEO212 Oral Capsule | Diffuse Astrocytoma, IDH-Mutant | Phase 1/2 | 134 | Recruiting | NCT06047379 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.